Zealand and Xeris Q4 ’18 Earnings Updates

Zealand and Xeris both released their respective Q4 ’18 earnings. Of note, Xeris did not have an associated call for investors. Recall, Xeris’s Gvoke glucagon rescue product PDUFA date is on June 10, 2019, and Zealand remains on track to file an NDA for its dasiglucagon HypoPal by YE ’19. Below, FENIX provides highlights and insights from the respective earnings releases.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.